BrainsWay Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

BrainsWay şirketinin toplam hissedar öz sermayesi $43.0M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $65.6M ve $22.7M dir. BrainsWay 'in FAVÖK'ü $730.0K faiz karşılama oranı -2 dur. Şirketin $47.9M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	-2x
Nakit	US$47.86m
Eşitlik	US$42.98m
Toplam yükümlülükler	US$22.65m
Toplam varlıklar	US$65.63m

Son finansal sağlık güncellemeleri

Recent updates

After Leaping 27% BrainsWay Ltd. (TLV:BWAY) Shares Are Not Flying Under The Radar

Aug 23

We Think BrainsWay (TLV:BWAY) Can Easily Afford To Drive Business Growth

May 03

BrainsWay Ltd.'s (TLV:BWAY) P/S Is Still On The Mark Following 26% Share Price Bounce

Dec 25

We're Hopeful That BrainsWay (TLV:BWAY) Will Use Its Cash Wisely

Dec 21

We're Hopeful That BrainsWay (TLV:BWAY) Will Use Its Cash Wisely

Sep 19

We're Keeping An Eye On BrainsWay's (TLV:BWAY) Cash Burn Rate

Jun 01

We Think BrainsWay (TLV:BWAY) Can Afford To Drive Business Growth

Aug 15

BrainsWay (TLV:BWAY) Is In A Good Position To Deliver On Growth Plans

May 13

BrainsWay (TLV:BWAY) Is In A Strong Position To Grow Its Business

Jan 31

What Is The Ownership Structure Like For Brainsway Ltd. (TLV:BWAY)?

Mar 02

What Type Of Returns Would Brainsway's(TLV:BWAY) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Jan 25

Brainsway Ltd. (TLV:BWAY): Is Breakeven Near?

Dec 26

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: BWAY 'nin kısa vadeli varlıkları ( $57.3M ) kısa vadeli yükümlülüklerini ( $12.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: BWAY şirketinin kısa vadeli varlıkları ( $57.3M ) uzun vadeli yükümlülüklerini ( $10.5M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: BWAY borçsuzdur.

Borcun Azaltılması: BWAY un 5 yıl önce borcu yoktu.

Borç Kapsamı: BWAY un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: BWAY şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

BrainsWay Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We Think BrainsWay (TLV:BWAY) Can Easily Afford To Drive Business Growth

We're Hopeful That BrainsWay (TLV:BWAY) Will Use Its Cash Wisely

We're Hopeful That BrainsWay (TLV:BWAY) Will Use Its Cash Wisely

We're Keeping An Eye On BrainsWay's (TLV:BWAY) Cash Burn Rate

We Think BrainsWay (TLV:BWAY) Can Afford To Drive Business Growth

BrainsWay (TLV:BWAY) Is In A Good Position To Deliver On Growth Plans

Recent updates

BrainsWay Ltd. to Report Q3, 2024 Results on Nov 12, 2024

BrainsWay Ltd. to Report Q3, 2024 Results on Nov 22, 2024

BrainsWay Ltd. announced that it has received $20.006615 million in funding from Valor Management LLC

Israel Ministry of Defense Clears BrainsWay Deep TMS™ for PTSD Reimbursement at Israeli

BrainsWay Ltd. Appoints Richard A. Bermudes, M.D. as Chief Medical Officer, Effective September 1, 2024

After Leaping 27% BrainsWay Ltd. (TLV:BWAY) Shares Are Not Flying Under The Radar

New major risk - Share price stability

Second quarter 2024 earnings released: EPS: US$0.02 (vs US$0.05 loss in 2Q 2023)

BrainsWay Ltd. Updates Revenue Guidance for the Full Year of 2024

BrainsWay Ltd. to Report Q2, 2024 Results on Aug 06, 2024

BrainsWay Ltd. Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS for Depression for the Month of June 2024

BrainsWay Ltd. Receives Expanded FDA Labeling to Treat Late Life Depression

BrainsWay Ltd., Annual General Meeting, Jun 17, 2024

First quarter 2024 earnings released: EPS: US$0.003 (vs US$0.07 loss in 1Q 2023)

BrainsWay Ltd. Reiterates Revenue Guidance for the Year 2024

We Think BrainsWay (TLV:BWAY) Can Easily Afford To Drive Business Growth

BrainsWay Ltd. to Report Q1, 2024 Results on May 08, 2024

BrainsWay Ltd. Announces Publish Review Results Highlighting Potential of Deep Transcranial Magnetic Stimulation (Deep TMS™) as a Novel Therapeutic Approach for Parkinson's Disease

Brainsway Announces Positive Results in Late-Life Depression Post-Marketing Analysis

Full year 2023 earnings released: US$0.13 loss per share (vs US$0.41 loss in FY 2022)

New major risk - Revenue and earnings growth

Brainsway Ltd. Provides Earnings Guidance for Full Year 2024

BrainsWay Ltd. to Report Q4, 2023 Results on Mar 06, 2024

New minor risk - Market cap size

BrainsWay Ltd. Announces New Rotational Field Technology in Two New Feasibility Studies

BrainsWay Ltd.'s (TLV:BWAY) P/S Is Still On The Mark Following 26% Share Price Bounce

We're Hopeful That BrainsWay (TLV:BWAY) Will Use Its Cash Wisely

Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0.15 loss in 3Q 2022)

BrainsWay Ltd. Announces Publishes the First Coverage Recommendations for Smoking Addiction Treatment Using TMS

BrainsWay Ltd. to Report Q3, 2023 Results on Nov 15, 2023

BrainsWay Announces Publication of Study Data on Accelerated Deep Transcranial Magnetic Stimulation (Deep TMS) for Depression

We're Hopeful That BrainsWay (TLV:BWAY) Will Use Its Cash Wisely

Forecast to breakeven in 2025

BrainsWay Ltd. to Report Q2, 2023 Results on Aug 09, 2023

We're Keeping An Eye On BrainsWay's (TLV:BWAY) Cash Burn Rate

Brainsway Ltd. Announces CFO Changes

No longer forecast to breakeven

BrainsWay Ltd. to Report Q1, 2023 Results on May 17, 2023

Full year 2022 earnings released: US$0.40 loss per share (vs US$0.21 loss in FY 2021)

BrainsWay Ltd., Annual General Meeting, Mar 20, 2023

BrainsWay Ltd. Appoints Ami Boehm as an Independent Director

BrainsWay Announces Extended Private Insurance Coverage in Washington State for the Treatment of OCD and Depression Utilizing Deep TMS™

Neuronetics Settles Litigation Against BrainsWay Ltd. and BrainsWay USA Inc

Third quarter 2022 earnings released: US$0.15 loss per share (vs US$0.05 loss in 3Q 2021)

No longer forecast to breakeven

BrainsWay Ltd. to Report Q3, 2022 Results on Nov 16, 2022

BrainsWay Ltd Announces Significant Private Insurance Coverage from Cigna Corporation for the Treatment of OCD Utilizing Deep TMS

BrainsWay Ltd. Receives New FDA Clearance for Treating Depression and Anxious Depression

We Think BrainsWay (TLV:BWAY) Can Afford To Drive Business Growth

Second quarter 2022 earnings released: US$0.07 loss per share (vs US$0.06 loss in 2Q 2021)

No longer forecast to breakeven

BrainsWay Ltd. to Report Q2, 2022 Results on Aug 10, 2022

BrainsWay Ltd. Announces Insurance Coverage by Israeli Ministry of Health for the Treatment of Depression

Brainsway Announces Positive OCD Coverage Policy from Blue Cross Blue Shield® (BCBS) Licensee Highmark BCBS for Deep TMS™

BrainsWay Ltd. Promotes Hadar Levy to Senior Vice President and Chief Operating Officer

BrainsWay (TLV:BWAY) Is In A Good Position To Deliver On Growth Plans

First quarter 2022 earnings released: US$0.06 loss per share (vs US$0.11 loss in 1Q 2021)

Neuronetics, Inc. Files Federal Lawsuit Against BrainsWay Ltd. for Misleading Psychiatrists and Patients

BrainsWay Ltd. to Present Expanded Post-Marketing Clinical Research for Major Depressive Disorder at Clinical TMS Society

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

BrainsWay Ltd. to Report Q4, 2021 Results on Mar 09, 2022

BrainsWay (TLV:BWAY) Is In A Strong Position To Grow Its Business

BrainsWay Announces Multiple Publications of New Real-World OCD Data for its Deep TMS™ System

Forecast to breakeven in 2024

Brainsway Announces Publication of Deep TMS™ Trial Results for Reduction of Heavy Drinking in Alcohol-Dependent Subjects

Third quarter 2021 earnings released: US$0.05 loss per share (vs US$0.04 loss in 3Q 2020)

Forecast to breakeven in 2023

FDA Clears BrainsWay Deep TMS System for Decreasing Anxiety Symptoms in Depressed Patients

Second quarter 2021 earnings released: EPS US$0.06 (vs US$0.03 loss in 2Q 2020)